Operating cash flow · Fiscal year 2025
| 1 | Johnson & JohnsonJNJ | $24.5B |
|---|---|---|
| 2 | UnitedHealth GroupUNH | $19.7B |
| 3 | AbbVieABBV | $19.0B |
| 4 | Novo Nordisk A SNVO | $18.0B |
| 5 | Eli LillyLLY | $16.8B |
| 6 | MerckMRK | $16.5B |
| 7 | AstraZenecaAZN | $14.6B |
| 8 | Bristol Myers SquibbBMY | $14.2B |
| 9 | HCA HealthcareHCA | $12.6B |
| 10 | PfizerPFE | $11.7B |